Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19. Certain immunosuppressant medications prevent the development of protective immunity followi...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 11; no. 12; p. 1855
Main Authors Elias, Luke B, Jaber, Aliya, Manzano, Margarita, Leekoff, Mark, Sylvester, Andrew, Tremblay, Matthew A
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.12.2023
MDPI
Subjects
Online AccessGet full text

Cover

Loading…